AC Vaccine technology Company Profile

16:12 EDT 20th September 2017 | BioPortfolio

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the animals were originally unresponsive to the protein. This work has been expanded by a number of researchers in various animal models. We now understand that a large number of T-cells react against the haptenized material and that a small percentage of the T-cells also react against the unmodified, natural material. We believe that tumor antigens, which are proteins, are similarly affected by haptenization.

Our AC Vaccine technology utilizes the patient’s tumor as the basis for a therapeutic vaccine. By extracting cancer cells from a tumor and then treating them with a hapten called dinitrophenyl (DNP), a vaccine is prepared that should be able to elicit a systemic immune response to the unmodified, native cancer cells. The induction of an immune response has been documented in a number of scientific publications. We believe that the best test of tumor immunity in patients is Delayed Type Hypersensitivity (DTH). DTH has long been used as a test for immunity to microbes, such as tuberculosis and is familiar to patients as the Tine test or PPD. DTH to cancer cells is tested in the same way, except that the patient’s cancer cells are the test agent. We have demonstrated that the DTH test to cancer cells is meaningful by showing a strong statistical relationship between the intensity of DTH and clinical outcomes, especially 5-year survival. We believe that the future acceptance of this relationship between DTH and clinical outcomes by the U.S. and European regulatory agencies is critical to the regulatory approval path for our AC Vaccine product candidates.


4520 MAIN STSTE 930
United States of America


Phone: 8169601333

News Articles [1662 Associated News Articles listed on BioPortfolio]

BE Licenses Takeda's Measles and Pertussis Vaccines for India and China

Biological E. (BE) negotiated two licensing agreements with Takeda for the latter’s measles and pertussis vaccines, which will allow BE to develop and commercialize affordable combination vaccines i...

Solid First-in-Human Results from Vaccine against Birth Defects

Hookipa has presented positive data from its first Phase I trial testing its vaccine technology against human cytomegalovirus (hCMV) infections. Hookipa, one of the top 10 biotechs we’re closely...

A short history of vaccine objection, vaccine cults and conspiracy theories

When we hear phrases like vaccine objection, vaccine refusal and anti-vaxxers, it's easy to assume these are new labels used in today's childhood vaccination debates.

'Groundbreaking Strides' Made in Zika Vaccine Research

WEDNESDAY, May 10, 2017 -- Development of a Zika vaccine is proceeding rapidly, but it still will be years before such a vaccine is available to the public, says the author of a new report on research...

Emergent BioSolutions gets global rights to Valneva's Zika vaccine technology

In its third deal this month, Emergent BioSolutions Inc. licensed exclusive worldwide rights to Valneva SE’s ZIKV Zika vaccine technology and know-how related to Zika drug development.

T Cell vaccine maker TapImmune looks to monetise expression tech

TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.

Investigational Vaccine Protected Monkeys from HIV-Like Virus

The vaccine adds three more targets to a human vaccine candidate that showed promise

When voting to approve a new vaccine, if you don’t know, say so

I abstained from an FDA committee vote on the safety of a new vaccine because it was impossible to tell if the vaccine increases heart attack risk.

PubMed Articles [1917 Associated PubMed Articles listed on BioPortfolio]

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.

We have previously shown that a novel DNA vaccine technology of codon optimization and the addition of ubiquitin sequences enhanced immunogenicity of a herpes simplex virus 2 polynucleotide vaccine in...

Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology.

Despite the fact that there had been multiple small outbreaks of Ebola Virus Disease, when a large outbreak occurred in 2014 there were no vaccines or drugs available for use. Clinical development of ...

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses.

Highly pathogenic avian influenza represents a severe public health threat. Over the last decade, the demand for highly efficacious vaccines against avian influenza viruses has grown, especially after...

Efficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine: The Need for an Alternative Development Plan.

Although vaccines would be the ideal tool for control, prevention, elimination, and eradication of many infectious diseases, developing of parasites vaccines such as malaria vaccine is very complex. T...

CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay.

Malaria is a severe infectious disease with relatively high mortality, thus having been a scourge of humanity. There are a few candidate malaria vaccines that have shown a protective efficacy in human...

Clinical Trials [4024 Associated Clinical Trials listed on BioPortfolio]

Immunity to Hepatitis B Vaccine

Infection and cancer is a major cause of death and morbidity, and may be preventable through vaccination. It is not fully understood at the molecular level why some people respond better t...

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on V

AMENDED 10/1/93: To evaluate the influence of prior immunization with an rgp120 vaccine on immune response to a subsequent immunization with a different strain of rgp120 (VEU 009X extensio...

Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects

In this study, subjects who were vaccinated with a meningococcal polysaccharide vaccine in a previous study (whose objectives & outcome measures are presented in a separate protocol postin...

Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

GSK Biologicals is developing in partnership with the Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative a candidate malaria vaccine for the routine immunizatio...

Autologous Vaccine for Follicular Lymphoma

This phase I study will evaluate the safety and tolerability of an autologous idiotype vaccine manufactured by magnICON technology for patients with relapsed follicular lymphoma who are in...

Companies [681 Associated Companies listed on BioPortfolio]

Hawaii Biotech, Inc.

Hawaii Biotech, Inc. is a privately held biopharmaceutical company focused on vaccine research and development. The company is targeting first world vaccines with potentially large markets and attract...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and ...

Variation Biotechnologies, Inc.

VBI is an emerging leader in the innovative formulation, delivery and development of vaccines. The Company’s powerful, proprietary technology platforms enable thermostable IM...

Pevion Biotech AG

Pevion Biotech AG is a fully independent Swiss vaccine company that develops innovative vaccines for unmet medical needs based on its clinically and commercially validated virosome technology. Its p...

Affinivax Inc.

Affinivax is advancing a next generation conjugate vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challengi...

More Information about "AC Vaccine technology" on BioPortfolio

We have published hundreds of AC Vaccine technology news stories on BioPortfolio along with dozens of AC Vaccine technology Clinical Trials and PubMed Articles about AC Vaccine technology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AC Vaccine technology Companies in our database. You can also find out about relevant AC Vaccine technology Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record